Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 nov. 2017 08h00 HE | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results

- Successfully Completed Upsized Initial Public Offering Raising $137.8 Million in Gross Proceeds - - Presented Preliminary Data from Phase 2 Clinical Trial of Setmelanotide in Bardet-Biedl Syndrome...
31 oct. 2017 08h01 HE | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome

-- Substantial Weight Loss Observed in 4 of 5 Patients -- -- Hunger Scores Improved in All 5 Treated Patients -- -- Results presented at ObesityWeek 2017 Meeting -- BOSTON, Oct. 31, 2017 (GLOBE...
10 oct. 2017 16h01 HE | Source: Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for...
04 oct. 2017 21h08 HE | Source: Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

BOSTON, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for treatment of rare...